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ABSTRACT
Ozonation to achieve removal of pharmaceuticals from wastewater effluents, with pH values in the upper and lower regions 
of the typical range for Swedish wastewater, was investigated. The main aim was to study the effects of varying pH values 
(6.0 and 8.0), and if small additions of H2O2 prior to ozone treatment could improve the removal and lower the reaction 
time. The effluents studied differed in their chemical characteristics, particularly in terms of alkalinity (65.3–427 mg∙ℓ−1 
HCO3-), COD (18.2–41.8 mg∙ℓ−1), DOC (6.9–12.5 mg∙ℓ−1), ammonium content (0.02–3.6 mg∙ℓ−1) and specific UV absorbance 
(1.78–2.76 ℓ∙mg−1∙m−1). As expected, lower ozone decomposition rates were observed in the effluents at pH 6.0 compared 
to pH 8.0. When pH 8.0 effluents were ozonated, a higher degree of pharmaceutical removal occurred in the effluent with 
low specific UV absorbance. For pH 6.0 effluents, the removal of pharmaceuticals was most efficient in the effluent with the 
lowest organic content. The addition of H2O2 had no significant effect on the quantitative removal of pharmaceuticals but 
enhanced the ozone decomposition rate. Thus, H2O2 addition increased the reaction rate. In practice, this will mean that the 
reactor volume needed for the ozonation of wastewater effluents can be reduced. 
Keywords: ozone; pharmaceuticals; hydrogen peroxide; wastewater effluents
INTRODUCTION
A number of pharmaceuticals of differing therapeutic class, 
along with their metabolites, have been detected in aquatic 
environments (Ternes, 1998; Kolpin et al., 2002; Fent et al., 
2006; Batt et al., 2006; Snyder, 2008; Verlicchi et al., 2012). The 
major source of these pharmaceuticals is considered to be the 
discharge of effluents by wastewater treatment plants (WWTPs) 
that are not designed for removing trace organic pollutants, in 
view of the recalcitrance of such pollutants to biodegradation 
and their limited biological activity, especially in cold climates.  
Accordingly, additional treatment following biological treat-
ment is called for.
Ozonation is one of the most promising technologies for 
the removal of organic micropollutants contained in waste-
water. The efficiency of ozone in removing pharmaceuticals and 
personal care products, both from water generally and from 
wastewater, has been tested in both laboratory- and pilot-scale 
experiments (Ternes et al., 2003; Huber et al., 2005; Buffle et al., 
2006a,b; Bahr et al., 2007; Benner and Ternes, 2009; Hollender 
et al., 2009; Hansen et al., 2010; Zimmermann et al., 2011). 
Ozone-based oxidation can be more energy-efficient than 
UV-based oxidation, especially when used for treatment of 
waters high in UV absorbance (Rosenfeldt et al., 2006; Hansen 
and Andersen, 2012). 
One of the benefits of using ozonation in aqueous solu-
tions is that the hydroxyl (OH) radicals that are produced will 
react non-selectively with pharmaceuticals, which could 
be an advantage for those pharmaceuticals that are diffi-
cult to degrade by direct reaction with ozone (Lee and Von 
Gunten, 2010). The OH radicals are generated through the 
self-decomposition of ozone in water at pH levels above 7, 
where the hydroxide ions are acting as initiators (Hoigne and 
Bader, 1983).  Laboratory experiments have shown that the 
addition of hydrogen peroxide (H2O2) enhances the decom-
position of ozone, promoting the production of OH radicals 
(Von Gunten, 2003). Furthermore, non-selective oxidation by 
highly reactive radicals usually enhances the reaction rates 
of ozone-resistant compounds, which will reduce the treat-
ment time required (Zwiener and Frimmel, 2000; Huber et al., 
2003). Balcioglu and Ötker (2003) reported that adding H2O2 
enhances both the UV absorbance (at 254 nm) removal and 
the decrease of COD in wastewater. The rapid reaction of OH 
radicals is preferable in practice since it reduces the reactor 
size needed for such treatment. The efficiency of ozone treat-
ment for the removal of pharmaceuticals can also depend 
upon the reactivity of the wastewater matrix in general 
(Nöthe et al., 2009). 
The present study aimed at investigating the impact of 
varying pH levels, within the natural interval in Sweden (pH 
6–8), on the removal of pharmaceuticals from wastewater efflu-
ents by the addition of ozone. It also determined if the reactiv-
ity of ozone can be promoted by addition of small amounts 
of H2O2 at low pH levels. Since the addition of H2O2 can be 
expected to enhance the decomposition of ozone to OH radi-
cals, it is of interest to investigate the effect this has in the case 
of effluents with a pH below 7, where the reaction rate can be 
expected to be lower and the pharmaceutical removal rate lower 
due to the lack of hydroxide ions that promote the decomposi-
tion of ozone. 
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MATERIALS AND METHODS
Overall experimental setup
Two effluents of relatively high pH (pH 8.0) were treated with 
ozone, whereas two other effluents, low in pH (pH 6.0), were 
treated with ozone in combination with H2O2. Treatment was 
carried out at these pH levels since they correspond to the 
upper and lower range of pH values typically found in Swedish 
WWTP effluents. The effluents selected were from plants with 
extended nitrogen and phosphorus removal. The difference 
in pH is due to the origin of the potable water (ground versus 
surface waters). Further, the effluents also differ with respect to 
other chemical parameters such as alkalinity and ammonium 
and organic matter content. The pharmaceuticals investi-
gated represent different therapeutic classes commonly used 
in Sweden, most of them having been found to be present in 
WWTP effluents (Falås et al., 2012). 
The production of OH radicals by ozone decomposition was 
followed indirectly through measuring the ozone concentra-
tion. The experiments were carried out initially in effluents with 
a pH range between 6 and 8, with the aim to determine the 
minimum amount of H2O2 needed to increase the decomposi-
tion of ozone. 
Chemicals
The H2O2 solution (30%) employed was purchased from Sigma-
Aldrich, the NaOH and H2SO4 being purchased from Merck 
(Germany). The pharmaceutical reference standards were 
purchased from different suppliers as analytical grade (> 98%) 
solids (Appendix:  Table S1). The stock solution of pharmaceuti-
cals was prepared in methanol at a concentration of 100 mg∙ℓ−1. 
The ozone stock solution was prepared in a glass bottle contain-
ing purified water (Millipore-Billerica, MA) and provided with 
a diffuser to disperse the generated ozone from a 1.0 g∙h−1 ozone 
generator (O3 Technology AB, Sweden) supplied with dry 
oxygen gas. The bottle was immersed in an ice bath to increase 
ozone solubility. Detailed description of the method is found in 
Antoniou and Andersen (2012).
WWTP effluents
The biologically-treated wastewater effluents investigated,  
differing in their characteristics and representing the typical 
variations in alkalinity, pH, and organic matter and ammo-
nium content, were taken from 4 municipal WWTPs in 
Sweden: Öresundsverket (Effluent 1), Klagshamn (Effluent 2), 
Uppsala (Effluent 3) and Käppala (Effluent 4). The effluent  
samples differed from one another in pH on the day of collec-
tion and were adjusted at the start of the experiment by use of 
either NaOH or H2SO4, so as to be exactly pH 6.0 or pH 8.0. 
Table 1 shows the quality parameters of the effluents.
Analysis
COD and NH4+-N were determined by use of the Hach Lange 
test kits LCK 114 and LCK 304. To measure alkalinity, a 25 mℓ 
sample was titrated with 0.05 M HCl to a pH of 4.5, and then 
the alkalinity in mg∙ℓ−1 HCO3- was calculated. DOC was meas-
ured on the basis of wet chemical oxidation, using a Shimadzu 
TOC-Vwp analyser. The UV-absorbance at 254 nm was meas-
ured using a Varian CARY50 Bio UV-Vis spectrophotometer. 
The specific UV absorbance (SUVA), an indicator of the dis-
solved aromatic carbon that the wastewater contains, known to 
affect the reactivity of DOC to ozone, was determined by nor-
malising UV absorbance at 254 nm to the DOC concentration 
(Weishaar et al., 2003). The O3 doses delivered were analysed by 
the colorimetric method of indigo (λ = 600 nm) through pre-
paring bottles of indigo trisulphonate solution in Milli-Q water 
in parallel with the treatment samples (Bader and Hoigne, 1981; 
Antoniou and Andersen, 2012). 
For pharmaceutical analysis, 100 mℓ samples of the treated 
effluent were filtered through a 0.45 µm membrane filter 
(Millipore) and were acidified to pH 3 by use of sulphuric 
acid. After SPE extraction, LC/MS/MS analysis of the extracts 
was carried out, using a triple-stage quadrupole MS/MS TSQ 
Quantum Ultra EMR (Thermo Fisher Scientific, USA) coupled 
with an Accela LC pump (Thermo Fisher Scientific, USA) and 
a PAL HTC autosampler (CTC Analytics AG, Switzerland) 
having a Hypersil GOLD aQTM column (50 mm x 2.1 mm ID x 
5 µm particles, Thermo Fisher Scientific, USA). The method of 
analysing pharmaceuticals was used earlier by Hörsing et al. 
(2011) and Hey et al. (2012). A detailed description and a full 
method evaluation are presented in Grabic et al. (2012). The 
ionisation mode, recoveries, relative standard deviations (RSD) 
and limit of quantification (LOQ) of the pharmaceuticals are 
given in the Appendix: Table S2.
Experimental setup
For the ozone consumption experiments carried out, the 
biologically-treated municipal wastewater was ozonated at 
different pH levels and O3 to H2O2 ratios. Samples were taken 
at different reaction times for analysis of the O3 content. For 
experiments involving pharmaceutical removal, the wastewater 
TABLE 1
Quality parameters of the effluent wastewaters studied
WWTPs Öresundsverket
Effluent 1
Klagshamn
Effluent 2
Uppsala
Effluent 3
Käppala
Effluent 4
High pH High pH Low pH Low pH
COD (mg∙ℓ−1) 41.8 32.4 18.2 35.4
DOC (mg∙ℓ−1) 9.2 9.0 6.9 12.5
Initial alkalinity (mg∙ℓ−1 HCO3-) 347.7 427 79.9 65.3
NH4
+-N (mg∙ℓ−1) 0.04 0.29 0.02 3.6
UV abs254nm (m-1) 16.4 24.8 16.0 29.5
pH (initial) 7.2 7.6 6.6 6.3
pH (adjusted) 8.0 8.0 6.0 6.0
SUVA (ℓ∙mg−1∙m−1) 1.78 2.76 2.31 2.36
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effluents from 4 WWTPs were spiked with pharmaceuticals so 
as to provide a nominal concentration of ~1 µg∙ℓ−1. The spiked 
effluents were then transferred into borosilicate glass bottles 
(Schott Duran®) to which different volumes of O3 stock solution 
were added to provide, in each case, a nominal concentration 
of between 1.4 and 10.7 mg∙ℓ−1 O3 for a total sample volume of 
150 mℓ. The bottles were covered with aluminium foil and were 
placed in a 15°C water bath for 2 h. For the O3 and H2O2 experi-
ments that were conducted, the H2O2 was added just prior to 
the addition of ozone. All treatment tests conducted were run 
in triplicate, a relative standard deviation of up to 20% between 
replicates being considered for data treatment.
RESULTS AND DISCUSSION
Determination of ozone concentration profiles at 
different pH
As can been seen in Fig. 1, the ozone concentration in the 
wastewater effluents decreased rapidly after the first minute of 
ozone addition. Thereafter, the rate of ozone decomposition 
decreased gradually and stabilised. This relatively fast ozone 
consumption was to be expected due to the matrix components 
in the wastewater consuming the oxidant. In addition, the 
decomposition of ozone tended to proceed faster at pH 8 than 
at pH 6, in accordance with the results of other studies, such 
as Hoigne and Bader (1981), using drinking water spiked with 
organic compounds, and Elovitz et al. (2000) which focused on 
surface water and groundwater. Wert et al. (2009) also dem-
onstrated the fast consumption of ozone in real wastewaters of 
varying organic carbon content.
When H2O2 was added to the effluents at H2O2/O3 ratios 
ranging from 2 to 0.25 (Fig. 1), ozone was almost completely 
consumed during the first minute. As could be expected, the 
effluent of high pH (pH 8) exhibited the fastest ozone decompo-
sition rate (< 1 min). An additional experiment was also carried 
out at pH 6.0, involving the use of lower doses of H2O2, result-
ing in significantly lower H2O2/O3 ratios of 0.05–0.10. As can be 
seen (Fig. 1), the differences in ozone removal rate between the 
samples are most obvious in the first minute or so of treatment, 
where the decomposition of ozone increased with an increase 
in the H2O2/O3 ratio for around 2 min, after which nearly all the 
ozone has been consumed.  
O3 concentration profiles in the WWTP effluents tested
On the basis of these findings, it is obvious that the addition 
of relatively small amounts of H2O2 is able to change the ozone 
concentration profile appreciably. To investigate this further, 
a set of experiments was carried out using 4 different effluent 
wastewaters (Table 1), two with relatively high pH and two 
with relatively low pH. The effluents, after pH adjustments 
to 8.0 and 6.0, respectively, were treated with ozone and the 
decomposition was followed (Fig. 2). In the high-pH effluents 
(Fig. 2A), about half of the ozone was already consumed during 
the first minute, especially in the case of Effluent 2. The differ-
ences observed can be attributed to the higher SUVA content in 
Effluent 2 than in Effluent 1 (Table 1). The relatively high con-
tent of aromatic compounds, indicated by the relatively high 
SUVA level, could explain the increased ozone consumption in 
the early stages of treatment, due to fast reactivity of aromatic 
compounds, as also observed by Westerhoff et al. (1999). At pH 
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Figure 2
Ozone consumption in WWTP effluents at pH 8.0 (A, Effluents 1 and 2) without H
2
O
2
 and at pH 6.0  
(B, Effluents 3 and 4) both with H
2
O
2
 (at a H
2
O
2
/O
3
 ratio of 0.10) and without     
Figure 1
Ozone consumption in the WWTP effluent (Effluent 1) at pH 8 (A) and at pH 6 (B) with different doses of H
2
O
2
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6.0, in contrast, Effluent 3 appears to have a much lower ozone 
demand than Effluent 4 (Fig. 2B), this probably being due to 
the lower organic content of Effluent 3, which is only about half 
that of Effluent 4. Similar to what can be seen above (Fig. 1), the 
addition of H2O2 to the effluent led to an increased decomposi-
tion of ozone, measured as a decline in ozone concentration.  
These findings show that it is important, when employ-
ing ozonation, to investigate the initial ozone demand of the 
wastewater due to matrix effects. The present findings also show 
that at low pH the combination of ozone and H2O2 reduces the 
reaction time, indicating that it is possible to reduce the size of 
the reaction tank employed for treatment.
Removal of pharmaceuticals by O3 and H2O2
In the ozonation of pH 8.0 effluents, a significant reduction in 
the different pharmaceuticals was found, especially in the case 
of Effluent 1 (Fig. 3A), even at relatively low doses of ozone. 
At the lowest dose (1.5 mg∙ℓ−1 O3), 9 of the 40 pharmaceuti-
cals (clomipramine, sulfamethoxazole, repaglinide, ethinyl 
estradiol, fexofenadine, codeine, naproxen, diltiazem and 
eprosartan) already showed removal rates of 90–100%; only 8 
of the pharmaceuticals (bupropion, oxazepam, levonorgestrel, 
memantine, fluconazole, flutamide, ketoprofen and ibuprofen) 
exhibited < 50% removal. As the ozone dose was increased, 
most of the pharmaceuticals, including the less reactive ones, 
were degraded. 
On the other hand, in Effluent 2 (Fig. 3B), the pharma-
ceuticals were poorly removed, even when the O3 dose was 
increased. This can be attributed to the high SUVA level (2.76 
as compared with 1.78) of this effluent. The high ozone reac-
tivity of the aromatic components of the DOC may have con-
tributed to the decrease in pharmaceutical removal from the 
effluent. Also, as can be observed in Fig. 3, some of the phar-
maceuticals in Effluent 1 exhibited a high level of removal in 
response to the lowest ozone dose but did not follow the same 
pattern of removal in Effluent 2. For example, both clomi-
pramine and repaglinide showed a high degree of removal at 
the lowest ozone dose, yet when treated with the same O3 dose 
in Effluent 2 it was only clomipramine for which the degree of 
removal was significant (~50%). This shows clearly that both the 
level of removal and the reactivity of pharmaceuticals can vary 
depending upon the composition of the wastewater matrix.
The efficiency of ozone in removing pharmaceuticals 
from pH 6.0 effluents (Fig. 4A) showed that ozone alone could 
remove > 90% of half of the pharmaceuticals present in Effluent 
3 at the lowest ozone dose (1.8 mg∙ℓ−1). When the dose was 
increased to 4.4 mg∙ℓ−1, all pharmaceuticals except fluconazole 
were degraded by over 90%. A still further increase in the 
ozone dose resulted in over 99% removal of all pharmaceuti-
cals, except fluconazole (93%) and ibuprofen (96%). In contrast, 
the ozonation of Effluent 4 resulted in > 90% degradation of the 
pharmaceuticals when rather high doses of ozone (> 5 mg∙ℓ−1) 
were employed (Fig. 4B). In comparison to the pH 8.0 effluent 
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Figure 3
The contribution of 
each level of ozone 
dose to the removal 
of pharmaceuticals 
in Effluent 1 (A) and 
Effluent 2 (B) during 
ozonation at pH 8.0
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(Effluent 1), the observed high 
removal of pharmaceuticals 
in the pH 6.0 effluent (Effluent 
3) is likely due to the very low 
organic content of this efflu-
ent (Table 1), which resulted 
in more ozone being available 
(Fig. 2B) to react with the 
pharmaceuticals.
Figure 5 illustrates the 
contribution of H2O2 addi-
tion to the removal of those 
pharmaceuticals that have 
been shown to have the lowest 
reactivity towards ozone. For 
fluconazole (Effluent 3), as 
can be seen, there was only 
a slight increase in removal 
after the addition of H2O2, 
whereas for ibuprofen no 
improvement in its removal 
occurred. Thus, the addi-
tion of H2O2 (at an H2O2/
O3 ratio of 0.08–0.13) to an 
initial ozone dose of 10 mg∙ℓ−1 
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could not be expected to have any appreciable impact on the 
removal of pharmaceuticals in this effluent. On the other hand, 
for Effluent 4, the addition of H2O2 was found to enhance the 
removal of ibuprofen, fluconazole, levonorgestrel, sulfamethox-
azole and ketoprofen by only 4–16% and of naproxenl by ~15%. 
The overall findings of this study show that reaction time 
can be reduced when ozone is combined with small amounts of 
H2O2, which will  be advantageous when practical implementa-
tion of the technology takes place.  As for most pharmaceu-
ticals, this addition has no impact on removal efficiency, i.e., 
neither increasing nor decreasing its removal. 
The majority of pharmaceuticals included in this study 
contained acidic and/or basic groups, having different and 
pH-dependent charges (positive, neutral or negative) and, as a 
result, may also differ in their tertiary chemical structure, as a 
function of pH. The pharmaceuticals that are acidic can be pro-
tolysed at pH 6, with no further changes occurring then when 
the pH is increased to 8. In contrast, those pharmaceuticals that 
have basic group(s) and low pKb values go from being unpro-
tolysed at pH 6 to being protolysed at pH 8, the charge thus 
changing from positive to neutral, which can result in a change 
in the tertiary structure. Those pharmaceuticals having both 
acidic and basic groups may also undergo changes in the charge 
and in their tertiary structure. This can be expected to have 
an impact on the oxidation rate. It is not possible, however, on 
the basis of the experiments carried out here, to draw any final 
conclusions regarding this.    
Table 2 provides an overview of the findings regard-
ing removal efficiencies for the pharmaceuticals that were 
investigated.  It can readily be seen that an ozone dose of 
around 5 mg∙ℓ−1 is sufficient to remove over half of the target 
pharmaceuticals, except in the case of Effluent 2, in which a 
much higher ozone dose may be required for removing a large 
fraction of the pharmaceuticals, this most likely being due to 
the higher SUVA level of Effluent 2. At the same time, it appears 
that, in the case of  wastewaters such as Effluent 3 that are 
low in pH and organic content, a reasonable dose of ozone to 
remove over 90% of the pharmaceuticals is around 5 mg∙ℓ−1.
The oxidation of pharmaceuticals may lead to the produc-
tion of by- and transformation products. Since these can be 
toxic to varying degrees as compared with the mother com-
pound, toxicity evaluation of a given technology should be 
performed before it is considered for implementation.    
CONCLUSIONS
The following conclusions can be drawn on the basis of the 
results of the study:
•	 Ozonation can be employed as an additional treatment step 
to enable trace pharmaceuticals to be removed effectively 
from wastewater effluents. 
•	 The amount of ozone required for the removal of pharma-
ceuticals is dependent upon the chemical composition of 
the wastewater and upon the target compounds, with the 
content of organic matter in general and its aromaticity 
being of considerable importance. 
•	 Ozone decomposition can be stimulated by adding hydro-
gen peroxide at low pH. The addition of hydrogen peroxide 
has only a limited impact on the quantitative removal of 
pharmaceuticals. However, it reduces the treatment time 
and, accordingly, the reaction volume needed, which will be 
advantageous in practice.  
TABLE 2
Pharmaceuticals for which at least 90% removal () occurs in each of the effluents when treated  
with ~ 5 mg∙ℓ−1 O3. (NA = compound not quantified)
Pharmaceuticals (High pH) (Low pH) (High pH) (Low pH)
Eff 1 Eff 2 Eff 3 Eff 4 Pharmaceuticals Eff 1 Eff 2 Eff 3 Eff 4
Amitriptyline     Hydroxyzine    
Atracurium  NA   Ibuprofen   
Beclomethasone      Irbesartan    
Biperiden     Ketoprofen    
Bisoprolol     Levonorgestrel    
Bupropion     Loperamide NA   
Carbamazepine     Maprotiline    
Cilazapril     Memantine    
Citalopram     Metoprolol    
Clomipramine     Naproxen    
Codeine     Orphenadrine    
Diclofenac     Oxazepam    
Diltiazem     Repaglinide    
Eprosartan     Risperidone    
Ethinyl estradiol  NA  NA Rosuvastatin    
Fexofenadine     Sertraline    
Fluconazole     Sulfamethoxazole    
Fluoxetine     Tramadol    
Flutamide     Trimethoprim    
Haloperidol     Venlafaxine    
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Appendix
Supplementary information: Removal of pharmaceuticals in WWTP effluents by ozone and hydrogen peroxide
TABLE S1
List of suppliers for pharmaceuticals and the corresponding internal standards used for quantification
Pharmaceuticals Supplier Internal standards Supplier
Amitryptiline Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Atracurium Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Beclomethasone Sigma-Aldrich (Steinheim, Germany) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany)
Biperiden Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Bisoprolol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Bupropion Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Carbamazepine Sigma-Aldrich (Steinheim, Germany) 2H10 - Carbamazepine Cambridge Isotope Laboratories (Andover, MA, USA)
Cilazapril LGC Standards (Middlesex, UK) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Citalopram Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Clomipramine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Codeine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Diclofenac Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Diltiazem Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Eprosartan CHEMOS GmbH (Regenstauf, Germany) 2H10 - Carbamazepine Cambridge Isotope Laboratories (Andover, MA, USA)
Ethinyl estradiol Sigma-Aldrich (Steinheim, Germany) 13C2 - Ethinyl estradiol Cambridge Isotope Laboratories (Andover, MA, USA)
Fexofenadine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Fluconazole Sigma-Aldrich (Steinheim, Germany) 13C3 - Trimethoprim Cambridge Isotope Laboratories (Andover, MA, USA)
Fluoxetine Sigma-Aldrich (Steinheim, Germany) 2H5 - Fluoxetine Cambridge Isotope Laboratories (Andover, MA, USA)
Flutamide Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Haloperidol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Hydroxyzine Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Ibuprofen Sigma-Aldrich (Steinheim, Germany) 13C3 - Ibuprofen Cambridge Isotope Laboratories (Andover, MA, USA)
Irbesartan CHEMOS GmbH (Regenstauf, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Ketoprofen Sigma-Aldrich (Steinheim, Germany) 13C3 
2H3 - Naproxen Cambridge Isotope Laboratories (Andover, MA, USA)
Levonorgestrel LGC Standards (Middlesex, UK) 13C2 – Ethinyl estradiol Cambridge Isotope Laboratories (Andover, MA, USA)
Loperamide Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Maprotiline Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Memantine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Metoprolol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Naproxen Sigma-Aldrich (Steinheim, Germany) 13C3 
2H3 - Naproxen Cambridge Isotope Laboratories (Andover, MA, USA)
Orphenadrine LGC Standards (Middlesex, UK) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Oxazepam Sigma-Aldrich (Steinheim, Germany) 2H5 - Oxazepam Sigma-Aldrich (Steinheim, Germany)
Repaglinide Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Risperidone LGC Standards (Middlesex, UK) 2H4 - Risperidone Sigma-Aldrich (Steinheim, Germany)
Rosuvastatin CHEMOS GmbH (Regenstauf, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Sertraline Sigma-Aldrich (Steinheim, Germany) 2H6 - Amitriptyline Cambridge Isotope Laboratories (Andover, MA, USA)
Sulfamethoxazole Sigma-Aldrich (Steinheim, Germany) 13C6 - Sulfamethoxazole Cambridge Isotope Laboratories (Andover, MA, USA)
Tramadol Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
Trimethoprim Sigma-Aldrich (Steinheim, Germany) 13C3 - Trimethoprim Cambridge Isotope Laboratories (Andover, MA, USA)
Venlafaxine Sigma-Aldrich (Steinheim, Germany) 13C2H3 - Tramadol Cambridge Isotope Laboratories (Andover, MA, USA)
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TABLE S2
Ionization mode, recoveries, relative standard deviation (RSD) and limit of 
quantification (LOQ) of the pharmaceuticals
Pharmaceuticals Ionization 
mode
Recovery (average 
of triplicate)
%
RSD 
%
LOQ
ng∙ℓ−1
Amitryptiline HESI 83.3 7.5 5
Atracurium HESI 85.8 7.2 0.5
Beclomethasone HESI 25.2 12.9 10
Biperiden HESI 106 8.4 0.1
Bisoprolol HESI 83.1 5.1 0.1
Bupropion HESI 96.3 4.7 0.1
Carbamazepine HESI 101 15.1 1
Cilazapril HESI 143 5.9 1
Citalopram HESI 83.6 8.5 5
Clomipramine HESI 72.7 11.4 0.5
Codeine HESI 86.7 24.0 0.5
Diclofenac HESI 42.1 4.4 10
Diltiazem HESI 107 3.8 0.5
Eprosartan HESI 62.3 4.3 5
Ethinyl estradiol APPI 85.7 4.1 10
Fexofenadine HESI 81.1 7.1 5
Fluconazole HESI 89.8 12.9 0.5
Fluoxetine HESI 97.0 11.4 5
Flutamide HESI 91.8 3.9 5
Haloperidole HESI 64.0 12.7 0.1
Hydroxyzine HESI 94.5 14.2 0.5
Ibuprofen APPI 62.4 7.4 10
Irbesartan HESI 109 2.6 0.5
Ketoprofen APPI 73.2 7.4 10
Levonorgestrel APPI 99.5 3.0 10
Loperamide HESI 61.6 15.7 0.5
Maprotiline HESI 84.1 7.4 5
Memantine HESI 85.7 7.7 0.5
Metoprolol HESI 82.9 1.3 5
Naproxen APPI 95.5 4.5 10
Orphenadrine HESI 94.7 11.2 0.1
Oxazepam HESI 97.4 1.1 5
Repaglinide HESI 93.4 8.6 0.5
Risperidone HESI 101 2.4 0.1
Rosuvastatin HESI 147 6.4 10
Sertraline HESI 71.2 16.5 10
Sulfamethoxazole HESI 97.3 4.3 5
Tramadol HESI 129 6.3 0.5
Trimethoprim HESI 109 10.7 0.1
Venlafaxine HESI 96.2 7.8 0.5
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